Coherus Oncology (NASDAQ:CHRS), founded in 2014 and headquartered in Redwood City, California, is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapies for the treatment of cancer. The company’s research platform centers on harnessing the body’s immune system to recognize and eliminate malignant cells. Its pipeline features a range of monoclonal antibody candidates, including anti–PD-1 and anti–TIGIT agents, as well as next-generation modulators targeting immune checkpoints such as CTLA-4 and CD28. Coherus’ development programs address multiple solid tumor indications, including non–small cell lung cancer, melanoma and head and neck cancers.
In addition to its innovative immuno-oncology pipeline, Coherus Oncology achieved a commercial milestone with the launch of UDENYCA™ (pegfilgrastim-cbqv), a biosimilar to Amgen’s Neulasta® designed to reduce the duration of chemotherapy-induced neutropenia. The company has also pursued strategic licensing partnerships to broaden its portfolio, notably in-licensing the anti–PD-1 therapy toripalimab from Junshi Biosciences for development in the United States and Canada. Through these collaborations, Coherus aims to bring both biosimilar and novel immunotherapy products to market.
Coherus conducts its clinical trials across North America, Europe and Asia, often partnering with leading academic institutions and contract research organizations to advance its candidates from early-stage dose-finding studies to pivotal registrational trials. The company’s global footprint supports a robust regulatory strategy and facilitates interactions with the U.S. Food and Drug Administration, the European Medicines Agency and other health authorities. Coherus places a strong emphasis on safety monitoring and biomarker-driven patient selection to optimize therapeutic outcomes.
Guided by CEO Dave Holland and a leadership team of seasoned professionals in clinical development, regulatory affairs and manufacturing, Coherus Oncology remains committed to the rapid advancement of its immuno-oncology portfolio. With a focus on scientific rigor and patient-centered innovation, the company seeks to deliver new treatment options that could improve survival and quality of life for individuals battling cancer worldwide.
